Anti-cmet antagonists
AssigneeGenentech, Inc.
InventorsMark S. Dennis, Karen Billeci, Judy Young, Zhong Zheng
Life of this patent
Estimating the term…
Abstract
The invention provides therapeutic anti-c-met antibodies, and compositions comprising and methods of using these antibodies.
Claims19
A method of modulating a disease associated with dysregulation of the HGF/c-met signaling axis, said method comprising administering to a subject an effective amount of an anti-c-met antibody, wherein the anti-c-met antibody comprises (a) a heavy chain variable domain comprising HVR1-HC, HVR2-HC and HVR3-HC sequence depicted in FIG. 13 (SEQ ID NO:
- 191-193);
- and (b) a light chain variable domain comprising HVR1-LC, HVR2-LC and HVR3-LC sequence depicted in FIG. 13 (SEQ ID NO:
- 183-185).
2:
- A method of treating a subject having cancer, said method comprising administering to the subject an effective amount of an anti-c-met antibody, wherein the anti-c-met antibody comprises (a) a heavy chain variable domain comprising HVR1-HC, HVR2-HC and HVR3-HC sequence depicted in FIG. 13 (SEQ ID NO:
- 191-193);
- and (b) a light chain variable domain comprising HVR1-LC, HVR2-LC and HVR3-LC sequence depicted in FIG. 13 (SEQ ID NO:
- 183-185).
The method of claim 2, wherein the cancer is lung cancer, brain cancer, kidney cancer, gastric cancer, colorectal cancer, pancreatic cancer, liver cancer, head and neck cancer, bladder cancer, cervical cancer, thyroid cancer and/or prostate cancer.
4:
- A method of treating a proliferative disorder in a subject, said method comprising administering to the subject an effective amount of an anti-c-met antibody, wherein the anti-c-met antibody comprises (a) a heavy chain variable domain comprising HVR1-HC, HVR2-HC and HVR3-HC sequence depicted in FIG. 13 (SEQ ID NO:
- 191-193);
- and (b) a light chain variable domain comprising HVR1-LC, HVR2-LC and HVR3-LC sequence depicted in FIG. 13 (SEQ ID NO:
- 183-185).
5:
- (canceled)
6:
- The method of claim 1, 2, or 4, wherein the heavy chain variable domain comprises FR1-HC, FR2-HC, FR3-HC and FR4-HC sequence depicted in FIG. 13 (SEQ ID NO:
- 187-90).
7:
- The method of claim 1, 2, or 4, wherein the light chain variable domain comprises FR1-LC, FR2-LC, FR3-LC and FR4-LC sequence depicted in FIG. 13 (SEQ ID NO:
- 179-182).
8:
- The method of claim 1, 2, or 4, wherein the heavy chain variable domain comprises FR1-HC, FR2-HC, FR3-HC and FR4-HC sequence depicted in FIG. 13 (SEQ ID NO:
- 187-90) and the light chain variable domain comprises FR1-LC, FR2-LC, FR3-LC and FR4-LC sequence depicted in FIG. 13 (SEQ ID NO:
- 179-182).
9:
- The method of claim 8, wherein the antibody comprises CH1 sequence depicted in FIG. 13 (SEQ ID NO:
- 194).
10:
- The method of claim 8, wherein the antibody comprises CL1 sequence depicted in FIG. 13 (SEQ ID NO:
- 186).
11:
- The method of claim 8, wherein the antibody comprises Fc sequence depicted in FIG. 13 (SEQ ID NO:
- 195).
12:
- The method of claim 8, wherein the antibody is monovalent and comprises a Fc region, wherein the Fc region comprises a first and a second polypeptide, wherein the first polypeptide comprises the Fc sequence depicted in FIG. 13 (SEQ ID NO:
- 195) and the second polypeptide comprises the sequence depicted in FIG. 14 (SEQ ID NO:
- 196).
13:
- The method of claim 1, 2, or 4, wherein the antibody is monovalent and comprises an Fc region.
14:
- The method of claim 2m further comprising treatment with a second therapeutic agent.
15:
- The method of claim 14, wherein the second therapeutic agent is a chemotherapeutic agent, an anti-angiogenic agent, or a growth inhibitory agent.
16:
- The method of claim 15, wherein the anti-angiogenic agent is an anti-VEGF antibody.
17:
- The method of claim 14 wherein administration is combined administration.
18:
- The method of claim 14, wherein administration is separate administration.
19:
- The method of claim 18, wherein separate administration of the anti-cmet antibody is prior to and/or following administration of the second therapeutic agent.
Dependencies are inferred from the claim text.